Maxime Robert-Halabi

Cardiologist with an interest in Cardio-oncology and echocardiography
Travelling/running enthusiast.

[Ramez Morcos, M.D. M.B.A @MorcosRamez]

If you have time to read the entire new HRS/PACES statement on antiarrhythmic drugs, go for it.

https://t.co/LslxUttOhq

If you don’t—and just want the meat of it—I asked ASTRA-6 to summarized the highest-yield, practice-changing points below.

And if you haven’t started using AI to keep up with the nonstop explosion of medical knowledge, try it today.

#EPeeps #Electrophysiology #AIinMedicine

[AHA Science @AHAScience]

In case you missed it, here are all late-breaking trial results from #ESCCongress

[European Society of Cardiology @escardio]

Tailored Treatment of Myocardial diseases, Endocarditis and Atrial Fibrillation - HOTLINE 1 👇

#ESCCongress

[NEJM @NEJM]

Presented at #ESCCongress:

In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: https://t.co/rISG8pcl17

Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke https://t.co/GvgayePOoC

@escardio

[DrJE-Salem @DrJESalem]

Restarting Immune Checkpoint Inhibitors After ICI Myocarditis: A Prospective Cohort | Circulation https://t.co/traQJaSJ3Y

[CardiovascularCorner @TrackYourHeart]

Arterial obstruction causing MI, stroke, or organ/limb infarction may result from acute fibrin cap rupture, thrombus extension, or embolism

[EACVI President @EACVIPresident]

🚀 New Era of Myocardial Strain unveiled at #ASE2025!
Key takeaways: 👉 Apply strain in #HF, valvular disease, & #CardioOnc.
Incredible consensus & collaboration 👏🏼 @ASE360 @EACVIPresident @JamesDThomasMD1 @mariellesc1 @DonalErwan @lpbadano @leylaelifsade @denisamuraru @s_e_petersen @DocStrom @aniela_petrescu @benayozbay @pfelissamburu @VDelgadoGarcia

[Maxime Robert-Halabi @HalabiMaxime]

@drjohnm A somewhat similar trial was published in NEJM last year - EPIC CAD - investigating edoxaban +/- asa in afib+chronic Cad patients - > similar results

[Davide Capodanno @DFCapodanno]

Even though we conducted it, this is not the study that will settle the question once and for all. However, I find this result increasingly plausible and compelling: if you plan a short DAPT after PCI and wish to de-escalate, stop aspirin, not the P2Y12 inhibitor.
https://t.co/CwohXQPOAC

[Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) @Basalus]

1/ The top 10 in #CardioOncology (2024) are here!
A landmark year with insights across prevention, screening, pathophysiology & prognosis. Let’s break down the essentials.
#CardioTwitter #OncoCardiology
[Ref: https://t.co/nQSybEOYR5]

[Mounir Basalus (Ⲃⲁⲥⲓⲗⲓⲟⲥ) @Basalus]

EHRA 2025 highlights:
•Key late-breaking trials
•New ESC/EHRA guidelines
•Practical consensus updates

Clear, concise, and clinical.
Read the full summary: 👇
#EHRA2025 #CardioTwitter #EPeeps

[DrJE-Salem @DrJESalem]

Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis: Venturing into the Unkown https://t.co/ehJ5KyFBn6

[Donald Tusk @donaldtusk]

Dear @ZelenskyyUa, dear Ukrainian friends, you are not alone.

[Mednomics @mednomics]

Cardiologist vs Nephrologist when IV diuretic is administered

[Maxime Robert-Halabi @HalabiMaxime]

#NewProfilePic

[AHA Science @AHAScience]

Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.

The 2024 Guideline for the Management of Hypertrophic Cardiomyopathy was published today in @CircAHA.

✍🏼 @SteveOmmen

📷 Recommended Evaluation & Testing for HCM

[Saad Ur Rahman @SaadUrRahman55]

Takeaways from #ACC2024. Late breaking trials - take home points @ACCinTouch

1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart transplantation, HF hospitalizations, outpatient worsening HF events.

[Emanuele Monda @MondaEmanuele]

Summary of trials presented at #ESCCongress2023

@escardio

#1

[Maxime Robert-Halabi @HalabiMaxime]

@argulian 2:1 sinoatrial block

[Maxime Robert-Halabi @HalabiMaxime]

@Blebthefrench @McGillFamMed Bravo!